{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=35",
    "query": {
      "intervention": "Branch II",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 4756,
    "total_pages": 476,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T15:55:02.571Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02218606",
      "title": "Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate 1000 mg po daily",
          "type": "DRUG"
        },
        {
          "name": "Cabazitaxel 25 mg/m2 IV",
          "type": "DRUG"
        },
        {
          "name": "prednisone 5 mg po BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 81,
      "start_date": "2014-08",
      "completion_date": "2023-10-13",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 4,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania • Norfolk, Virginia",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02218606"
    },
    {
      "nct_id": "NCT01280058",
      "title": "Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Wild-type Reovirus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2010-12",
      "completion_date": "2016-01-20",
      "has_results": true,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280058"
    },
    {
      "nct_id": "NCT05376358",
      "title": "Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression in Adolescence"
      ],
      "interventions": [
        {
          "name": "MoodRing App",
          "type": "DEVICE"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Ana Radovic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 73,
      "start_date": "2022-05-12",
      "completion_date": "2024-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05376358"
    },
    {
      "nct_id": "NCT00821652",
      "title": "Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod",
          "type": "DRUG"
        },
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nina Bhardwaj",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2009-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821652"
    },
    {
      "nct_id": "NCT06582615",
      "title": "Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cognitive Assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "Dietary Intervention",
          "type": "OTHER"
        },
        {
          "name": "Medical Device Usage and Evaluation",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2024-10-28",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Columbus, Ohio",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06582615"
    },
    {
      "nct_id": "NCT02896335",
      "title": "Palbociclib and Pembrolizumab In Central Nervous System Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm to Brain",
        "Recurrent Brain Metastases",
        "Progressive Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2017-02-02",
      "completion_date": "2029-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02896335"
    },
    {
      "nct_id": "NCT03611868",
      "title": "A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unresectable or Metastatic Melanoma or Advanced Solid Tumors",
        "Melanoma",
        "Uveal Melanoma",
        "P53 Mutation",
        "MDM2 Gene Mutation",
        "Cutaneous Melanoma",
        "Mucosal Melanoma",
        "Malignant Peripheral Nerve Sheath Tumors (MPNST)"
      ],
      "interventions": [
        {
          "name": "Phase 1b: APG-115+pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascentage Pharma Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2018-08-29",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Rogers, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03611868"
    },
    {
      "nct_id": "NCT02408016",
      "title": "Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Pleural Malignant Mesothelioma",
        "HLA-A*0201 Positive Cells Present",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Recurrent Pleural Malignant Mesothelioma",
        "Stage III Non-Small Cell Lung Cancer AJCC v7",
        "Stage III Pleural Malignant Mesothelioma AJCC v7",
        "Stage IIIA Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIB Non-Small Cell Lung Cancer AJCC v7",
        "Stage IV Non-Small Cell Lung Cancer AJCC v7",
        "Stage IV Pleural Malignant Mesothelioma AJCC v7",
        "WT1 Positive"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2015-05-22",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-09-13",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02408016"
    },
    {
      "nct_id": "NCT02760849",
      "title": "Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Deleterious BARD1 Gene Mutation",
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Deleterious BRIP1 Gene Mutation",
        "Deleterious EPCAM Gene Mutation",
        "Deleterious MLH1 Gene Mutation",
        "Deleterious MSH2 Gene Mutation",
        "Deleterious MSH6 Gene Mutation",
        "Deleterious PALB2 Gene Mutation",
        "Deleterious PMS2 Gene Mutation",
        "Deleterious RAD51C Gene Mutation",
        "Deleterious RAD51D Gene Mutation",
        "Hereditary Breast and Ovarian Cancer Syndrome",
        "Premenopausal"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oophorectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Salpingectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Salpingo-Oophorectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 50 Years · Female only"
      },
      "enrollment_count": 374,
      "start_date": "2016-05-02",
      "completion_date": "2041-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760849"
    },
    {
      "nct_id": "NCT03582774",
      "title": "Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68-labeled PSMA-11",
          "type": "RADIATION"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 193,
      "start_date": "2018-07-12",
      "completion_date": "2028-07-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-22T15:55:02.571Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • San Francisco, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03582774"
    }
  ]
}